Table 7.
Examples of recent studies on redox-sensitive liposomes
| Stage of study | Cargo | In-vivo tumor model | Components | Targeting ligand | Reference |
|---|---|---|---|---|---|
| In-vitro | Marker | _ | DOPE, Q-DOPE, DOPE-PEG | _ | (240) |
| In-vitro | DOX, Marker | _ | DSPC, DSPG, Ferrocene modified phospholipid prepared from DSPE and ferroceneacetic acid | _ | (241) |
| In-vitro | Redox-responsive docetaxel prodrug, Marker | _ | SPC, Chol, DSPE-PEG | _ | (242) |
| In-vitro | Marker | _ | POPC, POPE, Gallate derivative with three propargyl groups | _ | (243) |
| In-vitro | DOX | _ | Cerasome forming lipid with disulfide bond | _ | (244) |
| In-vitro | pDNA, Marker | _ | DOPE, Redox-sensitive gemini cationic Chol lipids | _ | (245) |
| In-vitro/In-vivo | Paclitaxel, siRNA, Marker | Breast cancer (4T1 cells) | SPC, Chol, redox-sensitive cationic lipid | _ | (234) |
| In-vitro/In-vivo | DOX | Murine osteosarcoma (MG63 cells) | SPC, Chol-SS-COOH, Chitooligosaccharides | _ | (233) |
| In-vitro/In-vivo | Redox-responsive docetaxel prodrug | Lung carcinoma (A549 cells) | SPC, Chol, DSPE-PEG | _ | (236) |
| In-vitro | DOX, Marker | _ | EPC, DOPE, lipid like conjugate with disulfide bond and a biotin moiety | anti-HER2 antibody | (237) |
| In-vitro | Marker | _ | DPPC, DOPE, CHEMS, DOPE-S-S-PEG | R8 peptide | (246) |
| In-vitro/In-vivo | DOX | Murine osteosarcoma (MG63 cells) | SPC, DOPE, DOTAP, Chol-SS-mPEG | Hyaluronic acid | (238) |
| In-vitro/In-vivo | Paclitaxel, Marker | Murine melanoma (B16F1) | SPC, Chol, DSPE-PEG, DSPE-SS- PEG5000 |
TAT peptide | (199) |
| In-vitro/In-vivo | Marker | Colon carcinoma (C26 cells) | EPC, Chol, Chol-S-S-PEG5000 | R8 peptide | (239) |
| In-vitro/In-vivo | DOX, Verapamil, Marker | Breast cancer (MCF7 cells) | EPC, Chol, Chol-PEG2000, Chol-S-S-PEG5000 | R8 peptide | (235) |
Abbreviations: CHEMS: Cholesteryl hemisuccinate; Chol: Cholesterol; Chol-PEG: Cholesterol anchored modified-(polyethylene glycol)-2000; Chol-SS-COOH: Cholesterol anchored reduction-sensitive COOH; Chol-SS-PEG: Cholesterol anchored reduction-sensitive-(polyethylene glycol)-2000; DOPE: 1,2-Dioleoylsn-glycero-3-phosphoethanolamine; DOPE-PEG: 1,2-Dioleoylsn-glycero-3-phosphoethanolamine (polyethylene glycol)-2000; DOPE-SS-PEG: 1,2-Dioleoylsn-glycero-3-phosphoethanolamine anchored modified (polyethylene glycol)-2000; DOTAP: 1,2-Dioleoyl-3-trimethylammonium-propan; DOX: Doxorubicin; DPPC: 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine; DSPC: 1,2-Distearoyl-sn-glycero-3-phosphocholine; DSPE: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine; DSPE-PEG: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-(polyethylene glycol)-2000; DSPG: 1,2-Distearoyl-snglycero-3-phospho-(1'-rac-glycerol); EPC: Egg phosphatidylcholine; HER2: Human epidermal growth factor receptor 2; pDNA: Plasmid DNA; POPC: 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPE: Palmitoyl-oleoyl-phosphoethanolamine; Q-DOPE: Quinone-dioleoyl phosphatidylethanolamine; R8 peptide: Octaarginine peptide; siRNA: Small (or short) interfering RNA; SPC: Soybean phosphatidylcholine; TAT peptide: (GRKKRRQRRRPQ) peptide